Literature DB >> 2146369

Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease.

B V Manyam1, E Giacobini, J A Colliver.   

Abstract

The caudate nucleus has the highest acetylcholinesterase (AChE) activity in the brain and it has been shown that autopsied brain tissue of patients with Huntington's disease (HD) have reduced levels of acetylcholine. Because of these findings, the cholinergic function in HD was studied by measuring cerebrospinal fluid (CSF) choline levels and AChE activity during a randomized, double-blind, cross-over, placebo-controlled clinical trial of isoniazid. While mean choline levels adjusted for age were lower compared with controls (P = 0.0007), AChE activity did not differ between HD patients and normal controls. Treatment with isoniazid had no significant effect on CSF choline levels or CSF AChE activity. CSF AChE activity showed a statistically significant increase with advancing age. The reduced level of choline in CSF of HD patients may reflect either a defect in choline transport into the brain or a decrease of choline-phospholipid output from the brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146369     DOI: 10.1007/bf00314742

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  Increase in rat brain acetylcholine induced by choline or deanol.

Authors:  D R Haubrich; P F Wang; D E Clody; P W Wedeking
Journal:  Life Sci       Date:  1975-09-15       Impact factor: 5.037

2.  Radiochemical assay for ACh: modifications for sub-picomole measurements.

Authors:  R E McCaman; J Stetzler
Journal:  J Neurochem       Date:  1977-03       Impact factor: 5.372

3.  Amphetamine effect on the choline concentration of human cerebrospinal fluid.

Authors:  L E Jönsson; J Schuberth; A Sundwall
Journal:  Life Sci       Date:  1969-09-01       Impact factor: 5.037

4.  Choline acetylase and glutamic acid decarboxylase in Huntington's chorea. A preliminary study.

Authors:  P L McGeer; E G McGeer; H C Fibiger
Journal:  Neurology       Date:  1973-09       Impact factor: 9.910

5.  Cerebrospinal fluid choline levels are decreased in Parkinson's disease.

Authors:  B V Manyam; E Giacobini; J A Colliver
Journal:  Ann Neurol       Date:  1990-06       Impact factor: 10.422

6.  Cerebrospinal fluid choline in extrapyramidal disorders.

Authors:  S M Aquilonius; B Nyström; J Schuberth; A Sundwall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-10       Impact factor: 10.154

7.  Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease.

Authors:  B V Manyam; T N Ferraro; T A Hare
Journal:  Brain Res       Date:  1987-04-07       Impact factor: 3.252

8.  Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders.

Authors:  K L Davis; L E Hollister; J Livesey; P A Berger
Journal:  Psychopharmacology (Berl)       Date:  1979-05-25       Impact factor: 4.530

9.  Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type.

Authors:  L Tune; S Gucker; M Folstein; L Oshida; J T Coyle
Journal:  Ann Neurol       Date:  1985-01       Impact factor: 10.422

10.  Cerebrospinal fluid as a reflector of central cholinergic and amino acid neurotransmitter activity in cerebellar ataxia.

Authors:  B V Manyam; E Giacobini; T N Ferraro; T A Hare
Journal:  Arch Neurol       Date:  1990-11
View more
  6 in total

1.  Antioxidants Reverse the Changes in the Cholinergic System Caused by L-Tyrosine Administration in Rats.

Authors:  Lara M Gomes; Giselli Scaini; Milena Carvalho-Silva; Maria L Gomes; Fernanda Malgarin; Luiza W Kist; Maurício R Bogo; Eduardo Pacheco Rico; Alexandra I Zugno; Pedro F P Deroza; Gislaine Z Réus; Airam B de Moura; João Quevedo; Gustavo C Ferreira; Patrícia F Schuck; Emilio L Streck
Journal:  Neurotox Res       Date:  2018-02-07       Impact factor: 3.911

2.  Platelet-derived extracellular vesicles in Huntington's disease.

Authors:  Hélèna L Denis; Jérôme Lamontagne-Proulx; Isabelle St-Amour; Sarah L Mason; Andreas Weiss; Sylvain Chouinard; Roger A Barker; Eric Boilard; Francesca Cicchetti
Journal:  J Neurol       Date:  2018-09-12       Impact factor: 4.849

3.  Acetylcholinesterase assay for cerebrospinal fluid using bupivacaine to inhibit butyrylcholinesterase.

Authors:  W H Kluge; H H Kluge; H I Bauer; S Pietsch; J Anders; R A Venbrocks
Journal:  BMC Biochem       Date:  2001-12-21       Impact factor: 4.059

Review 4.  Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.

Authors:  Gary X D'Souza; Henry J Waldvogel
Journal:  J Huntingtons Dis       Date:  2016-12-15

5.  Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington's Disease Patients.

Authors:  Natalia Szejko; Carmen Picón; Juan García-Caldentey; Justo Garcia de Yebenes; Jose Carlos Alvarez-Cermeño; Luisa Maria Villar; José Luis López-Sendón Moreno
Journal:  PLoS Curr       Date:  2018-08-31

Review 6.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.